Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.36 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17512820 | 1.00 | TDP1 (0.39) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17860915 | 0.91 | TDP1 (0.39) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15074351 | 0.89 | TDP1 (0.39) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17512759 | 0.83 | PYGM (0.39) | P2RY6P2RY2SMN1; SMN2P2RY4 | |
| SCHEMBL17512760 | 0.83 | PYGM (0.39) | P2RY6P2RY2SMN1; SMN2P2RY4 | |
| SCHEMBL17512823 | 0.83 | LMNA (0.40) | P2RY6LMNASMN1; SMN2P2RY14 | |
| SCHEMBL17512825 | 0.83 | LMNA (0.40) | P2RY6LMNASMN1; SMN2P2RY14 | |
| SCHEMBL15074422 | 0.80 | TDP1 (0.39) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17860666 | 0.80 | TDP1 (0.39) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17863929 | 0.80 | TDP1 (0.39) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3738969-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES FOR USE IN TREATING PNEUMOVIRINAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3183261-B1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES INC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200157137-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200087337-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2020-03-19 | — | — | US | disclosed |
| US-20190202852-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2019-07-04 | — | — | US | disclosed |
| US-9982006-B2 | 2′-chloro aminopyrimidinone and pyrimidine dione nucleosides | GILEAD SCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170327526-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2017-11-16 | — | — | US | disclosed |
| EP-3183261-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | Gilead Sciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9617295-B2 | 2′-chloro aminopyrimidinone and pyrimidine dione nucleosides | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160052953-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. | 2016-02-25 | — | — | US | disclosed |
| WO-2016028866-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | GILEAD SCIENCES, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157137-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | TYMP, DPYD, TYMS | TDP1 558/4885SLC28A1 131/4885SLC28A2 139/4885 |
| US-20190202852-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | TYMP, DPYD, TYMS | TDP1 558/4885SLC28A1 131/4885SLC28A2 139/4885 |
| US-20200087337-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | TYMP, DPYD, TYMS | TDP1 558/4885SLC28A1 131/4885SLC28A2 139/4885 |
| US-20170327526-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | TYMP, DPYD, TYMS | TDP1 558/4885SLC28A1 131/4885SLC28A2 139/4885 |
| US-20160052953-A1 | 2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES | TYMP, DPYD, TYMS | TDP1 558/4885SLC28A1 131/4885SLC28A2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.